Additionally, the phase 2 NCT05769725 trial is evaluating serplulimab in combination with DS versus DS alone as adjuvant treatment therapy in pathologic stage IIIc GC with PD-L1 CPS≥5/EBV+ (Epstein-Barr virus positive)/dMMR/MSI-H. The gene discussed is CD274; the disease is gastric cancer.